EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895

Maureen Trudeau, Brent Fraser

Current Oncology · 2023

DOI: 10.3390/curroncol30050380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Maureen Trudeau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CADTH read with interest the commentary published on 16 December 2022, entitled “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain” [...]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleTrastuzumabNeoadjuvant TherapyAdvisory CommitteesErb-b2 Receptor Tyrosine KinasesCanadaAntibodies, Monoclonal, Humanized

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasespertuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • CADTH, Ottawa, ON K1S 5S8, Canada.

Zitieren

APA

Trudeau, M., & Fraser, B. (2023). The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895. Current Oncology. https://doi.org/10.3390/curroncol30050380

Vancouver

Trudeau M, Fraser B. The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895. Current Oncology. 2023. doi:10.3390/curroncol30050380

BibTeX
@article{Trudeau2023,
  author = {Trudeau, Maureen and Fraser, Brent},
  title = {The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30050380}
}
Kostenlos starten →